Sulforaphane Blood Pressure Randomized Trial: What the Evidence Says

Quick Answer

Sulforaphane Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Substantial evidence has supported the beneficial role of healthy dietary factors in preventing the occurrence and development of CMDs and atherosclerosis in the aging population. [Wu Qi (2026); evidence level 2]
• Therefore, we performed a 12-month cluster-randomized controlled intervention trial to evaluate the effects of the RCMDR dietary pattern on clustered cardiometabolic risk, common carotid artery (CCA) atherosclerosis parameters, CMD risk factors (blood lipids, blood glucose, insulin sensitivity, homocysteine (Hcy), blood pressure) and body composition in community-dwelling older adults. [Wu Qi (2026); evidence level 2]
• Among these, glucoraphanin, a glucosinolate found abundantly in broccoli, has gained attention for its potential to convert to sulforaphane, a potent modulator of the Nrf2 antioxidant response pathway. [Cesanelli Leonardo (2026); evidence level 2]
• Figure 1 Markers of muscle damage include reductions in isometric and isokinetic peak torque, restricted elbow range of motion (ROM), increased arm girth, soreness, and elevated plasma creatine kinase (CK) activity and serve as dependent variables. [Cesanelli Leonardo (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For sulforaphane blood pressure randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Wu Qi (2026). Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial. DOI: 10.1016/j.jnha.2026.100902. PMCID: PMC13273878. PMID: 42269349. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13273878/
• Cesanelli Leonardo (2026). Short-Term Effects of Broccoli-Derived Glucoraphanin on Recovery from Eccentric Muscle Damage: A Double-Blind Randomized Crossover Study. DOI: 10.3390/nu18040710. PMCID: PMC12943077. PMID: 41754227. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12943077/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.